Is Valiant Organics overvalued or undervalued?

As of 17 November 2025, the valuation grade for Valiant Organics has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 33.75, an EV to EBITDA of 12.54, and a PEG ratio of 0.20, which suggests that while the company may have growth potential, its current price does not adequately reflect that potential compared to its earnings.
In comparison to its peers, Valiant Organics' PE ratio is higher than Cipla's 22.81 but lower than Sun Pharma's 36.69, indicating that while it is relatively attractive within its segment, it still faces pressure from higher-valued competitors. Additionally, its ROCE of 4.56% and ROE of 3.18% are lower than those of many peers, which further supports the overvaluation verdict. Recent stock performance has lagged behind the Sensex, with a YTD return of -7.03% compared to the Sensex's 8.72%, reinforcing concerns about its current valuation.